Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with $^{18}$F-FDG-PET and MIBI images

Sait Sager, Levent Kabasakal, Meltem Ocak, Helmut Maecke, Lebriz Uslu, Metin Halac, Sertac Asa, Gunes Sager, Cetin Onte and Bedii Kanmaz

**Aim** Various studies have been conducted for determining the most optimal method for the early diagnosis of local recurrent or distant metastatic thyroid cancers. The aim of this study was to evaluate the clinical utility of technetium-99m (Tc-99m)-labeled octreotide derivatives in the detection of recurrence or distant metastases in medullary thyroid cancer patients and to compare the lesions with those detected using $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG)-PET and Tc-99m MIBI studies in the same patient group.

**Patients and methods** Sixteen medullary thyroid cancer patients (two male and 14 female; mean age 52.0±14.1 years [range 13–72 years]) were included in this study. All patients underwent a whole-body scan 1 and 4 h after injection with octreotide derivatives and single photon emission computed tomography images were taken of the sites suspicious for metastasis. The lesions seen in Tc-99m HYNIC octreotide studies were compared with those seen in $^{18}$F-FDG-PET and Tc-99m MIBI studies.

**Results** Among the Tc-99m-labeled octreotide scintigraphy studies, nine were evaluated as true positive (56.2%) and one was evaluated as false positive (6.2%); six were false negative (37.5%). In 16 patients, the total number of lesions seen on octreotide scintigraphy was 21. Thirteen of the 16 patients underwent $^{18}$F-FDG-PET imaging. Of the 13 patients studied, 10 showed true-positive (76.9%) and three showed false-negative (23.1%) results. The total number of lesions seen on $^{18}$F-FDG-PET was 23. The Tc-99m MIBI study yielded positive results in seven of 16 patients (43.7%) and negative results in nine patients (56.3%). The total number of lesions on Tc-99m MIBI was 12.

**Conclusion** The Tc-99m-labeled somatostatin receptor scintigraphy analogs HYNIC-tyrosine octreotide and HYNIC-TATE are useful imaging alternatives in somatostatin receptor-expressing thyroid cancers. Radiolabling using these analogs is easy and they are readily available for routine use.

**Keywords:** $^{18}$F-fluorodeoxyglucose-PET, HYNIC-TATE, HYNIC-tyrosine octreotide, octreotide scintigraphy, Tc-99m MIBI

---

**Introduction**

Medullary thyroid carcinoma originates from parafollicular cells and secretes calcitonin [1]. After surgery, elevated calcitonin levels indicate the presence of metastatic or recurrent disease and the patient has to undergo multiple imaging procedures. An early diagnosis of local recurrence or distant metastases of medullary thyroid carcinoma can be achieved using several conventional imaging modalities [e.g. ultrasonography (USG), computed tomography (CT), MRI, and nuclear medicine imaging procedures such as positron emission tomography/CT (PET/CT)]. Scintigraphy with different types of radiopharmaceuticals (technetium-99m (Tc-99m) MIBI, Tc-99m DMSA, thallium-201), and scintigraphy with radiolabeled receptor ligands (octreotide scintigraphy) [2].

Somatostatin scintigraphy is most commonly used in the evaluation of somatostatin receptor-positive tumors such as carcinoid tumor, gastroenteropancreatic tumors (gastrinoma, insulinoma, glucagonoma, VIPoma), pheochromocytoma, paraganglioma, neuroblastoma, lung cancer (both small-cell and non-small-cell types), differentiated and medullary thyroid cancer, central nervous system tumors (meningioma, glioma, hypophyseal adenoma), lymphoma (both Hodgkin’s and non-Hodgkin’s type), breast cancer, ovarian cancer, and Merkel cell tumors. There is variable uptake in these tumors on somatostatin scintigraphy [3]. The half-life of natural somatostatin is short (1–2 min); therefore, many synthetic somatostatin analogs (octreotide, lanreotide, vapreotide, and depreotide) were developed. There are five different subtypes of somatostatin receptors, and natural somatostatin can
bind to all of them. The synthetic somatostatin analog octreotide can strongly bind to somatostatin receptor subtype 2 and weakly to subtype 5 [4].

Most medullary thyroid cancers express somatostatin receptors. Indium-111 (In-111) octreotide somatostatin receptor scintigraphy has been used to detect sites of recurrent or metastatic focus. There are several advantages of Tc-99m-labeled octreotide scintigraphy over In-111 octreotide scintigraphy. Image properties and image quality are better with Tc-99m than with In-111; further, whole-body images are taken at the first and fourth hours on the same day on using Tc-99m, whereas patients given an In-111-labeled radiopharmaceutical have to come the next day for 24th-hour imaging. Further, the radiation dose to the patient is lower on Tc-99m scintigraphy.

18F-Fluorodeoxyglucose (18F-FDG)-PET plays a crucial role in the detection of residual tumor or metastatic disease in patients with medullary thyroid cancer. Fasting is necessary before 18F-FDG injection, and diabetic patients should have regulated blood glucose levels. PET/CT with 18F-FDG has been proven to be better than other diagnostic tools in the detection of cervical and mediastinal lymph node metastases in medullary thyroid cancer [5].

The aim of this study was to evaluate the clinical utility of Tc-99m-labeled octreotide scintigraphy in the detection of tumor recurrence or metastases in patients with medullary thyroid carcinoma and to compare the lesions with those detected using PET/CT and Tc-99m MIBI studies.

Patients and methods
The study was approved by the local ethical committee and all patients gave informed consent before inclusion. Sixteen thyroid cancer patients [mean age 52.0±14.1 years (range 13–72 years)] who presented at our department and were diagnosed with medullary thyroid cancer with elevated calcitonin levels were included in this study. Two patients (13%) were male and 14 (87%) were female. All patients had undergone total thyroidecctomy 1–12 years earlier and were diagnosed with medullary thyroid carcinoma. In all patients, octreotide scintigraphy, MIBI scintigraphy, and 18F-FDG-PET/CT imaging were performed within a 2–14-day time interval. None of these patients received any further therapy during these studies. All patients underwent a whole-body scan 1 and 4 h after injection with octreotide derivatives, and single photon emission computed tomography (SPECT) images were acquired of the sites suspicious for metastases. The lesions seen on Tc-99m HYNIC-octreotide studies were compared with those seen in 18F-FDG-PET and Tc-99m MIBI studies.

The somatostatin analog Tc-99m HYNIC-TATE (HYNIC\(^{\text{N,N}}\)-diacetic acid as a coligand, was prepared in a sterile environment, boiled in water for 10 min, and left at room temperature for 15 min to cool. Each patient received an intravenous injection of 350–444 MBq (9–12 mCi) as a radiopharmaceutical. Whole-body scanning was carried out 1 and 4 h after injection, and SPECT images were acquired at the fourth hour. Images were acquired with a double-head gamma camera (Nuclide Spirit DH-V; Mediso, Budapest, Hungary) using a low-energy high-resolution collimator. A 140 keV energy peak±10% energy window was selected. SPECT images of the cervical region, mediastinum, lungs, and other suspicious locations observed on whole-body scanning were taken.

18F-FDG-PET imaging was performed with a six-slice multidetector CT integrated high-resolution PET scanner (Biograph LSO HI-REZ PET/CT; Siemens, Chicago, Illinois, USA). A minimum of 4 h of fasting and good hydration were maintained and blood glucose levels of each patient were measured using a glucometer (Medisense Optium; Xceed Abbott Diabetes Care Inc., Alameda, California, USA) before radiopharmaceutical injection. Anxious patients and especially young female patients received 5 mg of diazepam to reduce brown fat activity, following which they rested at room temperature. 18F-FDG [370–703 MBq (10–19 mCi)] was administered to patients with blood glucose levels lower than 150 mg/dl. After the injection, the patients rested for a further 45–60 min in a quiet, comfortable room for biodistribution and ideal tumor uptake of the radiopharmaceutical. Before imaging, all patients were asked to urinate to reduce urinary vesicle activity. First topogram images, then noncontrast low-dose CT images from the vertex to 1/3 of the upper portion of the thigh, and finally PET images were acquired while the patients lay in the supine position.

For Tc-99m MIBI imaging, 370–740 MBq (10–20 mCi) radiopharmaceutical was administered. Early images were taken 10–15 min after injection and late images were taken 2–3 h later with a dual-head gamma camera (Nuclide Spirit DH-V; Mediso) using a low-energy high-resolution collimator and selecting a 140 keV energy peak±10% window for Tc-99m.

Octreotide scintigraphy, 18F-FDG-PET, and MIBI scintigraphy images were evaluated by two separate nuclear medicine physicians at different times who were blinded to clinical data and the results of other imaging methods. The lesions observed in the images were divided into five anatomical groups: cervical (including the thyroid region), mediastinal, lung, bone, and abdomen and other regions. Images were compared for each lesion. The \( \chi^2 \)-test was used to determine whether there was a significant association between these imaging methods. The sensitivity, specificity, and number of lesions were determined for each imaging method.
Findings
Sixteen patients had sporadic medullary thyroid cancer. On Tc-99m-labeled octreotide scintigraphy, nine cases were evaluated as true positive (56.2%), and one was evaluated as false positive (6.2%); six were false negative (37.5%). In the 16 patients, the total number of lesions seen on octreotide scintigraphy was 21 (Table 1).

Thirteen of the 16 patients underwent 18F-FDG-PET imaging; of the 13 cases 10 were true positive (76.9%), and three were false negative (23.1%). The total number of lesions seen on 18F-FDG-PET was 23.

Tc-99m MIBI scintigraphy revealed seven of 16 positive cases (43.7%) and nine (56.3%) negative cases. The total number of lesions seen on Tc-99m MIBI was 12 (Figs 1 and 2).

Discussion
Somatostatin scintigraphy is used to detect the primary tumor focus for staging, preparation of therapy protocol, and assessment of therapy response in neuroendocrine tumors and in breast, brain, colon, and lung carcinomas [6]. The aim of somatostatin scintigraphy is to visualize tumors and tissues that express somatostatin receptors. In-111-labeled octreotide scintigraphy is the most common method for visualizing lesions with somatostatin receptors. In-111 octreotide was discovered by Krenning et al. [7] in the Netherlands, and octreotide scintigraphy was introduced as a reliable noninvasive imaging tool for detection of somatostatin receptor-expressing tumors. In-111 has some disadvantages with respect to its supplement, high cost, suboptimal imaging properties, and low resolution because of its medium energy and relatively high radiation dose to the patient. For this reason, new somatostatin analogs are being labeled with Tc-99m instead. In our study, we used the new somatostatin analog HYNIC-TATE labeled with Tc-99m.

It might be difficult to find a remnant or recurrent tumor focus in medullary thyroid cancer patients with high postoperative serum calcitonin levels. Detection of recurrence or distant metastasis is crucial for clinical assessment and selection of candidates for reoperation. Conventional methods such as neck USG, abdominal USG, spiral CT, and MRI are being used to detect recurrence or distant metastasis. However, sensitivity of all of these anatomical imaging modalities may be low because of postoperative changes and limited imaging properties. Scintigraphic modalities, such as Tc-99m MDP, thallium-201 chloride, Tc-99m MIBI, Tc-99m tetrofosmin, In-111 octreotide, and 18F-FDG-PET/CT, are the nuclear medicine whole-body imaging modalities for the detection of recurrence or metastatic disease in this group of patients.

Medullary thyroid carcinoma is a type of neuroendocrine tumor, which expresses somatostatin receptor subtype 2 (30–50%) and subtype 5 to a lesser extent [8]. Because of its somatostatin receptor expression, In-111 octreotide scintigraphy had been used to detect recurrence in medullary thyroid carcinoma patients with high levels of calcitonin and carcinoembryogenic antigen. Kwekkeboom et al. [9] reported the sensitivity of somatostatin scintigraphy to be 65% in medullary thyroid carcinoma detection.

De Groot and colleagues compared In-111 octreotide scintigraphy with 18F-FDG-PET in 26 medullary thyroid carcinoma patients with high levels of calcitonin. 18F-FDG-PET could detect malign focus in 13 of 26 patients (50%), whereas In-111 octreotide scintigraphy was positive for four of 21 patients. When lesions were compared, 18F-FDG-PET could detect 53 lesions and In-111 octreotide scintigraphy could detect 12. Sensitivity of 18F-FDG-PET and In-111 octreotide scintigraphy was 96 and 41%, respectively [10].

In the study by Parisella and colleagues, the aim was to detect recurrence and distant metastasis with Tc-99m tyrosine octreotide (HYNIC-TOC) in five patients with high levels of calcitonin after total thyroidectomy. Tc-99m TOC scintigraphy showed positive results in all five patients, and a total of 15 lesions were detected. When In-111 octreotide scintigraphy was performed in the same patient group, only three patients were found to be positive, and eight lesions were detected. All five patients were 18F-FDG-PET positive, and a total of 11 lesions were detected with PET. Parisella et al. [11] found more
lesions using octreotide scintigraphy compared with 18F-FDG-PET.

Lodish et al. [12] found that In-111 octreotide scintigraphy is less sensitive than conventional imaging modalities in detecting the full extent of metastatic disease in children and adolescents with hereditary medullary thyroid carcinoma.

In the study by Czepczyński and colleagues, octreotide scintigraphy using Tc-99m HYNIC-TOC showed 20 true-positive, four true-negative, one false-positive, and seven
false-negative results in a total of 26 medullary thyroid cancer patients. They found the sensitivity of octreotide scintigraphy with Tc-99m HYNIC-TOC to be 74.1% and the specificity to be 80.0%, demonstrating that these results were better than those obtained by other imaging methods [13].

In our study, octreotide scintigraphy was true positive in nine of 12 patients, and a total of 21 lesions were visualized. Ten of 13 patients showed true-positive results on 18F-FDG-PET, and a total of 23 lesions were detected. MIBI was true positive in seven of 16 patients, with a total of 12 lesions detected.

When we compare the total effective doses of these imaging methods, Tc-99m-labeled octreotide imaging is seen to involve the lowest radiation dose to the patients. Grimes et al. [14] reported the mean effective dose of Tc-99m HYNIC-TOC to be 4.6±1.1 mSv. The effective dose of 18F-FDG-PET/CT and whole-body Tc-99m MIBI imaging for adults is 0.019 (0.070) and 0.015 (0.056) mSv/MBq (rem/mCi), respectively [15,16].

Fig. 2

SPECT images of Tc-99m HYNIC octreotide scintigraphy in a 51-year-old female patient with medullary thyroid carcinoma. There is increased uptake in the mediastinum (arrow), which is the same lesion in PET/CT slices. CT, computed tomography; SPECT, single photon emission computed tomography; Tc-99m, technetium-99m.
Conclusion
Tc-99m-labeled somatostatin scintigraphy is an easy and promising imaging modality in medullary thyroid carcinoma patients with high levels of calcitonin. In comparison with In-111 octreotide scintigraphy, its availability and application is easier. Further, it has better image resolution and involves less radiation exposure to the patient. It has a higher sensitivity and a greater ability to detect lesions compared with MIBI; however, compared with 18F-FDG-PET, its sensitivity in detecting lesions is lower. Nevertheless, it can be used as an alternative imaging method when 18F-FDG-PET is not available. In addition, it is recommended when 18F-FDG-PET results are found to be negative. Our study suggests that Tc-99m-labeled octreotide could be considered an alternative to In-111-labeled octreotide, and further evaluation with larger numbers in a sufficiently powered study to enable statistical analysis should be undertaken.

Acknowledgements
There are no conflicts of interest.

References
1. Leboulleux S, Baudin E, Travagl J, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004; 61:299–310.
2. Gao Z, Biersack H, Ezziddin S, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol 2004; 130:649–656.
3. Jensen RT. Role of somatostatin receptors in gastrointestinal and pancreatic tumors. In: Lamberts SWJ, Dogliotti L, editors. The expanding role of octreotide I: advances in oncology. Bristol: BioScientifica Ltd; 2002. pp. 45–71.
4. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. Tc-99m-HYNIC-Tyr3-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with In-111-octreotide. J Nucl Med 2000; 41:1114–1119.
5. Al-Nahhas A, Khan S, Gogbashian A, Banti E, Rampin L, Rubello D. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy [review]. In Vivo 2008; 22:109–114.
6. Kalsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25:498–511.
7. Krenning EP, Bakker WH, Breman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radiomiminated analogue of somatostatin. Lancet 1989; 1:242–244.
8. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37:912–916.
9. Kwekkeboom DJ, Reubi JC, Lambert SWJ, Bruining HA, Mulder AH, Oei HY, Krenning EP. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76:1413–1417.
10. De Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11:786–794.
11. Parisella M, D’Alessandria C, van de Bossche B, Chianelli M, Ronga G, Papini E, et al. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biother Radiopharm 2004; 19:211–217.
12. Lodish M, Daglaklis UJ, Chen CC, Sinai N, Whitcomb P, Aikin A, et al. (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. J Clin Endocrinol Metab 2012; 97:E207–E212.
13. Czepczyn ´ski R, Kosowicz J, Mikołajczak R, Ziemnicka K, Gryczyn´ska M, Sowirski J. New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma. Pol Arch Med Wewn 2006; 116:853–860.
14. Grimes J, Celler A, Birkenfeld B, Schcherbinin S, Listewnik MH, Piwowarska-Biiska H, et al. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors. J Nucl Med 2011; 52:1474–1481.
15. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47:885–895, Erratum in: J Nucl Med 2006; 47:903.
16. Silverstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 2012; 53:1633–1651.